Brief: Zura Bio Ltd Tibulizumab (ZB-106) Was Well Tolerated And Neutralized Il-17A And Baff In A Phase 1 Study In Patients With Sjogren's Syndrome
14/06/2024 12:37
June 14 (Reuters) - Zura Bio Ltd ZURA.O :
* ZURA BIO LTD: TIBULIZUMAB (ZB-106) WAS WELL TOLERATED AND
NEUTRALIZED IL-17A AND BAFF IN A PHASE 1 STUDY IN PATIENTS WITH
SJOGREN'S SYNDROME
* ZURA BIO LTD: TREATMENT WITH TIBULIZUMAB WAS GENERALLY
WELL
TOLERATED IN PATIENTS WITH SJOGREN'S SYNDROME
Source text for Eikon: ID:nBw2YTTBqa
Further company coverage: ZURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zura Bio
See all newsZura Bio Ltd reports results for the quarter ended June 30 - Earnings Summary
Zura Bio Q2 net loss widens as R&D expenses rise
Zura Bio Ltd expected to post a loss of 20 cents a share - Earnings Preview
Brief: Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zura Bio Expands Leadership Team With Appointment Of Muzammil Mustufa As Chief Business Officer